Newpath Partners
Venture capitalActively deployingBoston · Seed–Series A · 3 people tracked
Also known as NEWPATH MANAGEMENT, L.P.
Find your way into Newpath Partners
540 people in our graph share verified history with the Newpath Partners team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Led by physician-scientist Tom Cahill, they form companies from academic discoveries in gene editing and regenerative medicine, offering company-formation expertise, board experience, and a high formation-and-exit track record.
Source: firm website, verified Sep 15, 2026.
Team · 3 people
from public directories
What they invest in
from 20 of 21 portfolio companiesBiotech ×17Medical Devices ×15Healthtech ×7Deep Tech ×6AI & Machine Learning ×5Digital Health ×3Marketing Tech ×1Retail Tech ×1
HQs:United States×14
Investments · 21 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 22024 · 22023 · 42022 · 12021 · 22020 · 113 dated
Prime Medicine develops one-time genetic therapies using Prime Editing, a gene editing technology developed in David R.
BiotechDeep TechHealthtechMedical Devices
Andrew Anzalone(Co-founder and Head of Platform)inDavid Liu(Co-founder)inAllan Reine(Chief Executive Officer)inMohammed Asmal(Chief Medical Officer)inAnn Lee(Chief Technical Officer)inSvetlana Makhni(Chief Financial Officer)in
Co-investorsARCH Venture PartnersGV (Google Ventures)F-Prime CapitalOUP (Osage University Partners)Samsara BioCapital
Neumora is a clinical research company developing investigational medications, with a focus on conducting clinical trials to obtain regulatory approval and make treatments available to patients.
BiotechDeep TechDigital HealthMedical DevicesWatertown, US
Paul L. Berns(Chairman and Chief Executive Officer)Joshua Pinto(Executive Officer)Tamara Tompkins(Executive Officer)inKari Stefansson(Director)Maykin Ho(Director)Alaa Halawa(Director)
Co-investorsARCH Venture PartnersCatalio Capital Management, LPF-Prime CapitalK2 HealthVenturesMercury FundPremier Partners+3 more
Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.
BiotechDeep TechMedical Devices
David Liu, PhD(Founder)Alan Saghatelian, PhD(Co-Founder)David LiuinAlan Saghetelian
Co-investorsCRV (Charles River Ventures)Nextech InvestRaptor GroupSamsara BioCapitalBiotechnology Value FundCasdin Capital+1 more
Magnet Biomedicine develops TrueGlue™, a molecular glue discovery platform for designing small molecule therapeutics that induce novel protein-protein interactions to treat cancer and immune disorders.
AI & Machine LearningBiotechMedical DevicesBoston, US
Benjamin F. Cravatt, PhD(Founder & Advisor)David A. Spiegel, MD, PhD(Founder & Advisor)Michael Rosbash, PhD(Founder & Advisor)Richa Saxena, PhD(Founder & Advisor)Stuart Schreiber, PhD(Founder & Advisor)Brian Safina(President & Chief Executive Officer)in
Co-investorsARCH Venture PartnersTaiho Ventures, LLC
nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.
BiotechDeep TechMedical Devices
Luke Gilbert, PhDKeith Joung, MD, PhDDavid Liu, PhDAngelo Lombardo, PhDLuigi Naldini, MD, PhDJonathan Weissman, PhD
Co-investorsAtlas VentureARCH Venture PartnersDCVC (Data Collective)F-Prime Capital5AM VenturesDCVC Bio+1 more
Autobahn Therapeutics develops orally administered small molecule prodrugs using a brain-targeting chemistry platform to create regenerative medicines for central nervous system (CNS) disorders.
BiotechDeep TechMedical DevicesSan Diego, US
Kevin Finney(Chairman, President and CEO)inJohn Borkholder(Executive Officer)in
BoardKristina Burow(Director)inTimothy Anderson(Director)Philip J DeSouza(Director)
Board seatThomas Cahill· per SEC Form D
Co-investorsARCH Venture PartnersCanaan PartnersMonograph Capital PartnersPfizer Venture InvestmentsSamsara BioCapital
DermBiont develops SM-030, a topical drug candidate targeting melasma, a skin pigmentation disorder, by inhibiting PKC-beta to address the underlying cause of hyperpigmentation.
BiotechDigital HealthMedical DevicesBoston, US
Robert Brucker(Executive Officer)inKarl R. Beutner(Executive Officer, Director)inNichola Eliovits(Executive Officer, Director)inMax Dawson(Executive Officer)in
BoardWilder Ramsey(Director)inJennifer Lee(Director)
Board seatDaniel Yadegar· per SEC Form D · $45.3M raise · filed Nov 2024
Co-investorsCivilization Ventures Management, LlcJoyance PartnersOlive Tree CapitalStart CapitalToba CapitalValia Ventures
BiotechBoston, US
Nagesh Mahanthappa, Ph.D.(Director)Luba Greenwood(Director)in
BoardAmir Nashat, Ph.D.(Treasurer and Secretary)Susan Langer(President)
Board seatThomas J. Cahill· per SEC Form D
Co-investors5AM VenturesCathay Health
Aera Therapeutics develops genetic medicines using next-generation delivery technologies and precision payloads optimized for specific diseases.
AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, US
Feng Zhang, Ph.D.(Scientific Founder & Board Observer)Akin Akinc, Ph.D.(Chief Executive Officer & Board Director)
Co-investorsARCH Venture PartnersLux CapitalF-Prime CapitalGV (Google Ventures)JDRF T1D Fund
YourBio Health develops the TAP Device with HALO technology, a needle-free blood collection system that uses micro-needles thinner than an eyelash to enable virtually painless blood draws.
HealthtechMedical Devices
Co-investorsRaptor Group
CREATE Medicines is a clinical-stage biotech company that develops in vivo mRNA immune cell programming therapies.
BiotechDigital HealthHealthtechMedical DevicesSan Francisco, US
Daniel Getts(Founder and CEO)inBrett Kaplan(Chief Financial and Business Officer)inMarcus Lowe(Executive Officer, Director)Dhruv Amin(Executive Officer, Director)
Co-investors8VCRaptor Group
Eledon Pharmaceuticals is a clinical-stage biotechnology company developing immunology-based therapies, with a focus on protecting transplanted organs from rejection and treating autoimmune and neurodegenerative diseases including ALS.
AI & Machine LearningBiotechMedical Devices
Steven Perrin(President and Chief Scientific Officer)
Co-investorsJDRF T1D FundBiotechnology Value Fund
Leal 360 is a retail-focused customer platform for LATAM that combines a CDP, campaign automation, loyalty programs, and NPS with an AI decision engine, connecting to a business's POS to turn purchase data into personalized marketing and loyalty actions.
AI & Machine LearningMarketing TechRetail Tech
Co-investorsAspira CapitalAxon Partners GroupCapria VenturesFuel Venture CapitalLEAP Global PartnersSalkantay Ventures+1 more
Metsera was a clinical-stage biotechnology company developing injectable and oral medicines for obesity and metabolic diseases, including next-generation GLP-1 and amylin-based therapies.
BiotechHealthtechMedical DevicesNew York, US
Clive A. Meanwell(Director)Christopher J. Visioli(Executive Officer)inBrian Hubbard(Executive Officer)inChristopher Whitten Bernard(Executive Officer, Director)Steven Marso(Executive Officer)
BoardKristina Burow(Director)in
Co-investorsAlpha Wave GlobalARCH Venture PartnersF-Prime CapitalGV (Google Ventures)RA CapitalSoftBank Vision Fund
CREATE Medicines develops in vivo CAR immunotherapy using proprietary mRNA-LNP technology to program T cells, NK cells, and myeloid cells directly within the body for cancer, autoimmunity, and fibrosis.
AI & Machine LearningBiotechHealthtechMedical DevicesCambridge, US
Daniel Getts, Ph.D.(Chief Executive Officer, Cofounder, Board Director)
Co-investorsARCH Venture Partners8VCHatteras Venture Partners
A pharmaceutical company developing therapeutics across oncology, hematology, neuroscience, immunology, and cardiovascular disease with a pipeline of 50 compounds targeting 40+ disease areas.
BiotechHealthtechMedical Devices
Co-investorsAndreessen HorowitzARCH Venture PartnersiGlobe PartnersAgent CapitalREDMILE
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
AveloChroma Medicine, Inc.Rinascera TherapeuticsSeventh Sense Biosystems
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 4
2 IPOs · 2 acquisitions · showing 3Prime MedicineNASDAQ: PRMENeumora TherapeuticsNASDAQ: NMRAMetseraacq. by Pfizer
Portfolio news
latest coverage across their companies
Prime Medicine · biospace.com · Sep 3, 2026
Leal · dot.la · Aug 21, 2026
Neumora Therapeutics · dailypolitical.com · Jul 16, 2026
Rinascera Therapeutics · globenewswire.com · Jul 16, 2026
nChroma Bio · contagionlive.com · Jun 25, 2026
Myeloid Therapeutics · trial.medpath.com · May 15, 2026
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Prime Medicine | 5.1% | $17.00 | Oct 2022 | $83.4M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Newpath Partners made?
- Newpath Partners has 21 tracked investments, 4 of which have exited, including 4 dated in the last 24 months.
- What stage does Newpath Partners invest at?
- Newpath Partners invests at the Seed, Series A stages.
- What is Newpath Partners's typical check size?
- Newpath Partners typically writes checks of $50K – $10M.
- What sectors does Newpath Partners focus on?
- Newpath Partners focuses on Biotech, Medical Devices.
- Where is Newpath Partners located?
- Newpath Partners is headquartered in Boston, US.
- Does Newpath Partners lead rounds?
- Newpath Partners typically participates in rounds rather than leading them.
Images
Similar investors
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.
Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.
Plum Alley Investments is a venture investment firm that provides investors access to vetted early-stage technology opportunities and allocations, focusing on the convergence of computation, hardware innovation, and machine intelligence.
Kairos Ventures is an investment firm that backs ideas, patents, and businesses originating from leading universities and scientists.